These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

410 related items for PubMed ID: 38441582

  • 1. Cardiac Amyloidosis Due to Transthyretin Protein: A Review.
    Ruberg FL, Maurer MS.
    JAMA; 2024 Mar 05; 331(9):778-791. PubMed ID: 38441582
    [Abstract] [Full Text] [Related]

  • 2. Design and Rationale the SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study.
    Ruberg FL, Blaner WS, Chiuzan C, Connors LH, Einstein AJ, Fine D, Helmke S, Kurian D, Pandey S, Raiszadeh F, Rodriguez C, Sabogal N, Teruya S, Winburn M, Chung WK, Cohn E, Miller EJ, Kelly JW, Maurer MS.
    J Am Heart Assoc; 2023 Apr 18; 12(8):e028534. PubMed ID: 37066788
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
    Paton DM.
    Drugs Today (Barc); 2019 Dec 18; 55(12):727-734. PubMed ID: 31942875
    [Abstract] [Full Text] [Related]

  • 5. Tafamidis: A Review in Transthyretin Amyloid Cardiomyopathy.
    Lamb YN.
    Am J Cardiovasc Drugs; 2021 Jan 18; 21(1):113-121. PubMed ID: 33469827
    [Abstract] [Full Text] [Related]

  • 6. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS).
    Ruberg FL, Maurer MS, Judge DP, Zeldenrust S, Skinner M, Kim AY, Falk RH, Cheung KN, Patel AR, Pano A, Packman J, Grogan DR.
    Am Heart J; 2012 Aug 18; 164(2):222-228.e1. PubMed ID: 22877808
    [Abstract] [Full Text] [Related]

  • 7. Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans.
    Buxbaum JN, Ruberg FL.
    Genet Med; 2017 Jul 18; 19(7):733-742. PubMed ID: 28102864
    [Abstract] [Full Text] [Related]

  • 8. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
    Sekijima Y.
    J Neurol Neurosurg Psychiatry; 2015 Sep 18; 86(9):1036-43. PubMed ID: 25604431
    [Abstract] [Full Text] [Related]

  • 9. Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]).
    Miller AB, Januzzi JL, O'Neill BJ, Gundapaneni B, Patterson TA, Sultan MB, López-Sendón J.
    Am J Cardiol; 2021 Jun 01; 148():146-150. PubMed ID: 33667442
    [Abstract] [Full Text] [Related]

  • 10. DISCOVERY: prevalence of transthyretin (TTR) mutations in a US-centric patient population suspected of having cardiac amyloidosis.
    Akinboboye O, Shah K, Warner AL, Damy T, Taylor HA, Gollob J, Powell C, Karsten V, Vest J, Maurer MS.
    Amyloid; 2020 Dec 01; 27(4):223-230. PubMed ID: 32456532
    [Abstract] [Full Text] [Related]

  • 11. RNA-targeting and gene editing therapies for transthyretin amyloidosis.
    Aimo A, Castiglione V, Rapezzi C, Franzini M, Panichella G, Vergaro G, Gillmore J, Fontana M, Passino C, Emdin M.
    Nat Rev Cardiol; 2022 Oct 01; 19(10):655-667. PubMed ID: 35322226
    [Abstract] [Full Text] [Related]

  • 12. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.
    Maurer MS, Grogan DR, Judge DP, Mundayat R, Packman J, Lombardo I, Quyyumi AA, Aarts J, Falk RH.
    Circ Heart Fail; 2015 May 01; 8(3):519-26. PubMed ID: 25872787
    [Abstract] [Full Text] [Related]

  • 13. Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature.
    Adam RD, Coriu D, Jercan A, Bădeliţă S, Popescu BA, Damy T, Jurcuţ R.
    ESC Heart Fail; 2021 Aug 01; 8(4):2380-2396. PubMed ID: 34089308
    [Abstract] [Full Text] [Related]

  • 14. Therapy of ATTR Cardiac Amyloidosis: Current Indications.
    Di Lisi D, Di Stefano V, Brighina F, Galassi AR, Novo G.
    Curr Probl Cardiol; 2023 Feb 01; 48(2):101487. PubMed ID: 36336119
    [Abstract] [Full Text] [Related]

  • 15. Sporadic Cardiac Amyloidosis by Amyloidogenic Transthyretin V122I Variant.
    Nehashi T, Oikawa M, Amami K, Kanno Y, Yokokawa T, Misaka T, Yamada S, Kunii H, Nakazato K, Ishida T, Takeishi Y.
    Int Heart J; 2019 Nov 30; 60(6):1441-1443. PubMed ID: 31666456
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Transthyretin Amyloid Cardiomyopathy-Current and Future Therapies.
    Yadav JD, Othee H, Chan KA, Man DC, Belliveau PP, Towle J.
    Ann Pharmacother; 2021 Dec 30; 55(12):1502-1514. PubMed ID: 33685242
    [Abstract] [Full Text] [Related]

  • 18. Update on Disease-Specific Biomarkers in Transthyretin Cardiac Amyloidosis.
    Hood CJ, Hendren NS, Pedretti R, Roth LR, Saelices L, Grodin JL.
    Curr Heart Fail Rep; 2022 Oct 30; 19(5):356-363. PubMed ID: 35930129
    [Abstract] [Full Text] [Related]

  • 19. Transthyretin cardiac amyloidoses in older North Americans.
    Dharmarajan K, Maurer MS.
    J Am Geriatr Soc; 2012 Apr 30; 60(4):765-74. PubMed ID: 22329529
    [Abstract] [Full Text] [Related]

  • 20. Cardiac amyloidosis: a review and report of a new transthyretin (prealbumin) variant.
    Hesse A, Altland K, Linke RP, Almeida MR, Saraiva MJ, Steinmetz A, Maisch B.
    Br Heart J; 1993 Aug 30; 70(2):111-5. PubMed ID: 8038017
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.